Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Roche Holding AG Basel American Depositary Shares (OP: RHHBY )

35.50 +0.21 (+0.60%)
Streaming Delayed Price Updated: 12:33 PM EST, Nov 22, 2024 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Roche Holding AG Basel American Depositary Shares

< Previous 1 2
...
10 11 12 13 14 15 16 17 18
...
27 28 Next >
Roche's Muscular Atrophy Treatment Improves Motor Function In Pretreated Patients
Via Benzinga
Roche To Introduce Next-Generation Portfolio Of COVID-19 Rapid Tests
Via Benzinga
Positive New Data for Genentech’s Evrysdi in Largest Trial Ever Undertaken in Patients With Previously-Treated Spinal Muscular Atrophy (SMA)
From Genentech
Via Business Wire
Despite Advancement, Benefits From Alzheimer's Drugs May Be Limited, Say Researchers
Via Benzinga
FDA Approves Expanded Use Of Roche's Influenza Treatment
Via Benzinga
EXCLUSIVE: Lineage Cell Establishes New R&D Facility In US, Expands Israel-Based Facility
Lineage Cell Therapeutics Inc (NYSE: LCTX) has opened a new research and development facility in Carlsbad, California. 
Via Benzinga
Stock Market Falls, S&P 500 Hits Bear Lows; Biogen, Nike, Micron Are Key Movers: Weekly Review
The major indexes fell, with the S&P 500 breaking below bear market lows. 
Via Investor's Business Daily
These Stocks Are On The Radar After Biogen-Eisai's Surprising Alzheimer's Trial Win
Via Benzinga
This Analyst Believes Biogen's Lecanemab Data Not 'Slam Dunk' For Complete CMS Approval
Via Benzinga
2 Sympathy Plays To Watch For In The Wake Of Biogen's Positive Alzheimer's Drug Data
Biogen Inc. (NASDAQ: BIIB) and partner Eisai Co. Ltd. 
Via Benzinga
FDA To Review Smaller Number Of Emergency Use Requests For COVID-19 Tests
Via Benzinga
COVID-19 Complacency Pushes Identification Of New Variants To Back Seat, WHO Warns
The World Health Organization (WHO) warned that it struggles to identify and 
Via Benzinga
Multiple Sclerosis Is A Crowded Space, But This Stock Is A Potential 6X Multi-bagger
Via Benzinga
Europe Approves First Bispecific Antibody From Roche For Two Eye Disorders
Via Benzinga
WHO Recommends Against Roche, GSK's COVID-19 Therapies Rendering Them Obsolete
Due to the lack of effectiveness against omicron and the variants, World Health Organization (WHO) no longer recommends using two COVID-19 antibody therapies. 
Via Benzinga
Something Unusual Is Happening Right Now With Biotech Stocks Like Catalyst, Vertex, Neurocrine And BioMarin
The market is struggling, yet biotech stocks are acting like it's good times again. Here's why. 
Via Investor's Business Daily
A Major October Catalyst Could Make This Eye Stock A Ten Bagger, Analyst Says
Chardan initiated coverage on Outlook Therapeutics Inc (NASDAQ: OTLK) with a Buy rati 
Via Benzinga
A Quick Look At The OTC Markets' Most-Active Securities In August - Here's What You Need to Know
While July gave markets around the world a breather, August reestablished 2022’s choppy financial conditions. 
Via Benzinga
Good Therapeutics Announces Acquisition of Conditionally Active PD-1-regulated IL-2 Program by Roche
From Good Therapeutics
Via Business Wire
No More Free COVID-19 At-Home Tests, Federal Government Says
CNBC reported that the federal government is set to suspend its offer of free at-home COVID-19 tests by Friday, September 2, without congressional au 
Via Benzinga
Citi Is Bullish On This Large Pharma Stock On Upcoming Data Readout From Diabetes Candidate
Citi has increased peak risk-adjusted Eli Lilly And Co's (NYSE: LLY) tirzepatide forecasts (diabetes/ obesity/NASH) to more than $25 billion (previously $15 billion, consensus of around $16 billion).  
Via Benzinga
Week In Review: Everest Sells Trodelvy Rights Back To Gilead For $455 Million
Shanghai Everest Medicines returned rights for Trodelvy to Immunomedics, now a subsidiary of Gilead Sciences, in an agreement worth up to $455 million ($280 million upfront). 
Via Talk Markets
China-Based Jemincare Inks Prostate Cancer Drug Pact With Roche's Genentech
Via Benzinga
Roche's Polivy Combo Regime Under FDA Review For Type Of Blood Cancer
Via Benzinga
OTC Markets' Most Active Securities Sees A Shake-up In July
July gave world markets a breather from 2022’s poor financial conditions. 
Via Benzinga
FDA Accepts Supplemental Biologics License Application for Genentech's Polivy Combination for People With Previously Untreated Diffuse Large B-Cell Lymphoma
From Genentech
Via Business Wire
Genentech Announces FDA Approval of Xofluza to Treat Influenza in Children Aged Five and Older
From Genentech
Via Business Wire
Biotech Daily: Cancer Causing Impurities In Merck's Diabetic Drug, Vir Bio-GSK Shun FDA Submission Plans For COVID-19 Treatment, Aethlon's Monkeypox Trial
Here's a roundup of top developments in the biotech space over the last 24 hours: 
Via Benzinga
Amgen's Lumakras/Keytruda/Tecentriq Combo Data Flags Safety Concern
Via Benzinga
These 2 Under-The-Radar Stocks Traded More Than $1B Each Last Month
The month of July saw $37.3 billion in trading volume for stocks that trade on the OTCQK and OTCQB. While some of the stocks that trade over-the-counter are considered penny stocks based on their share... 
Via Benzinga
< Previous 1 2
...
10 11 12 13 14 15 16 17 18
...
27 28 Next >
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.